Nanobiotix names board member, creates new department
This article was originally published in Scrip
Executive Summary
Nanobiotix, a clinical-stage company developing cancer therapies, has named company chief financial officer Philippe Mauberna to its executive board. Mr Mauberna joined the company in May 2013. Furthermore, the Paris, France-based firm has named Sarah Gaubert head of its newly created communication and public affairs department. Prior to joining the firm, Ms Gaubert was an advisor to the French Presidency and several ministries including the Ministry of Health.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.